Search

Investigators, FS-ZONE. 2015. “Pioglitazone in Early Parkinson’s Disease: A Phase 2, Multicentre, Double-Blind, Randomised Trial. NINDS Exploratory Trials in Parkinson Disease (NET-PD). Lancet Neurol 2015;14:795-803.”. Lancet Neurol.

Nutt, JG, AD Siderowf, M Guttman, PN Schmidt, RA Hauser, and . 2014. “Mobility, Mood and Site of Care Impact Health Related Quality of Life in Parkinson’s Disease. Parkinsonism Relat Disord 2014;20:274-9.”. Parkinsonism Relat Disord.

Cicchetti, F, S Lacroix, G Cisbani, N Vallieres, M Saint-Pierre, I St-Amour, R Tolouei, J Skepper, RA Hauser, and . 2014. “Mutant Huntingtin Is Present in Neuronal Grafts in Huntington’s Disease Patients. Ann Neurol 2014;76:31-42.”. Ann Neurol.

“Hauser RA. How to Dose Carbidopa and Levodopa Extended Release Capsules (Rytary). Clinical Medicine Journal 2015;1:34-7.”. 2015. Clinical Medicine Journal.

Pahwa, R, CM Tanner, RA Hauser, K Sethi, S Isaacson, D Truong, L Struck, et al. 2015. “Amantadine Extended Release for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASED Study). Mov Disord 2015;30:788-95.”. Mov Disord.

O’Brien, CF, R Jimenez, RA Hauser, SA Factor, J Burke, D Mandri, and JC Castro-Gayol. 2015. “NBI-98854, a Selective Monoamine Transport Inhibitor for the Treatment of Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study. Mov Disord 2015;30:1681-7.”. Mov Disord.

Espay, AJ, PA LeWitt, RA Hauser, A Merola, M Masellis, and AE Lang. 2016. “Neurogenic Orthostatic Hypotension and Supine Hypertension in Parkinson’s Disease and Related Synucleinopathies: Prioritisation of Treatment Targets. Lancet Neurol 2016;15:954-66.”. Lancet Neurol.

Rascol, O, RA Hauser, F Stocchi, CJ Fitzer-Attas, Y Sidi, V Abler, CW Olanow, and AFU Investigators. 2016. “Long-Term Effects of Rasagiline and the Natural History of Treated Parkinson’s Disease. Mov Disord 2016;31:1489-1496.”. Mov Disord.

Hauser, RA, SH Mehta, D Kremens, D Chernick, and AE Formella. 2021. “Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Dec;10(2):739-751. Doi: 10.1007/S40120-021-00256-1.”. Neurol Ther.

Oertel, W, K Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, R Ehret, et al. 2017. “Randomized, Placebo-Controlled Trial of ADS-5102 (amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 3). Mov Disord 2017;32:1701-1709.”. Mov Disord.